Eric von Hofe

Eric von Hofe is President & COO, Affyimmune.


Tuning and Tracking CAR-T Cells for Safer and More Effective Treatment for Solid Tumors

With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.